DelMar Pharmaceuticals Inc (DMPI.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2017||Chairman of the Board|
|48||2017||President, Chief Operating Officer, Director|
|64||2017||Interim Chief Executive Officer, Director|
|50||2013||Chief Financial Officer|
|66||2013||Chief Scientific Officer, Director|
- BRIEF-Delmar Pharmaceuticals' interim CEO Saiid Zarrabian reports purchase of 60,900 shares of co's common stock on Nov 14
- BRIEF-Delmar Pharmaceuticals names Saiid Zarrabian interim CEO
- BRIEF-DelMar Pharmaceuticals CEO Jeffrey Bacha buys 10,000 shares of co's common stock on Oct 6
- BRIEF-DelMar Pharmaceuticals announces $10 million registered direct offering
- BRIEF-Delmar Pharmaceuticals receives IND allowance from FDA